Occurrence, ecotoxicological effects and risk assessment of antihypertensive pharmaceutical residues in the aquatic environment - A review

Chemosphere

Volumn 138, Issue , 2015, Pages 281-291

  Godoy, Aline A ^a   Kummrow, Fábio ^b   Pamplin, Paulo Augusto Z ^a  

^a FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiotensin II receptor antagonists; Angiotensin converting enzyme inhibitors; Aquatic ecotoxicology; Beta blockers; Calcium channel blockers; Emerging contaminants

Indexed keywords

METABOLITES;

ANGIOTENSIN CONVERTING ENZYME INHIBITORS; BETA-BLOCKERS; CALCIUM CHANNEL BLOCKERS; ECO-TOXICOLOGY; EMERGING CONTAMINANT; RECEPTOR ANTAGONISTS;

RISK ASSESSMENT;

ACEBUTOLOL; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETAXOLOL; BISOPROLOL; CAPTOPRIL; CARAZOLOL; DILTIAZEM; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; NADOLOL; OLMESARTAN; OXPRENOLOL; PRACTOLOL; PROPRANOLOL; SOTALOL; SURFACE WATER; TIMOLOL; VALSARTAN; VERAPAMIL; WATER POLLUTANT;

AQUATIC ENVIRONMENT; CALCIUM; CONCENTRATION (COMPOSITION); DRUG; ECOTOXICOLOGY; ENVIRONMENTAL RISK; HYPERTENSION; LITERATURE REVIEW; METABOLITE; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SURFACE WATER;

ACTIVATED SLUDGE; ECOTOXICITY; REVIEW; RISK ASSESSMENT; WASTE WATER TREATMENT PLANT; WATER CONTAMINATION; ANALYSIS; ANIMAL; AQUATIC SPECIES; CHEMISTRY; DRUG EFFECTS; ECOTOXICOLOGY; PROCEDURES; TOXICITY; WATER POLLUTANT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUATIC ORGANISMS; ECOTOXICOLOGY; RISK ASSESSMENT; WATER POLLUTANTS, CHEMICAL;

EID: 84940904228     PISSN: 00456535     EISSN: 18791298     Source Type: Journal    
DOI: 10.1016/j.chemosphere.2015.06.024     Document Type: Review

References (81)

1. Bayen S., Zhang H., Desai M.M., Ooi S.K., Kelly B.C. Occurrence and distribution of pharmaceutically active and endocrine disrupting compounds in Singapore's marine environment: Influence of hydrodynamics and physical-chemical properties. Environ. Pollut. 2013, 182:1-8. 10.1016/j.envpol.2013.06.028.
2. Bayer A., Asner R., Schüssler W., Kopf W., Wei K., Sengl M., Letzel M. Behavior of sartans (antihypertensive drugs) in wastewater treatment plants, their occurrence and risk for the aquatic environment. Environ. Sci. Pollut. Res. 2014, 21:10830-10839. 10.1007/s11356-014-3060-z.
3. Bendz D., Paxéus N.A., Ginn T.R., Loge F.J. Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Höje River in Sweden. J. Hazard. Mater. 2005, 122:195-204. 10.1016/j.jhazmat.2005.03.012.
4. Berkner S., Thierbach C. Biodegradability and transformation of human pharmaceutical active ingredients in environmentally relevant test systems. Environ. Sci. Pollut. Res. 2014, 21:9461-9467. 10.1007/s11356-013-1868-6.
5. Bouissou-Schurtz C., Houeto P., Guerbet M., Bachelot M., Casellas C., Mauclaire A.C., Panetier P., Delval C., Masset D. Ecological risk assessment of the presence of pharmaceutical residues in a French national water survey. Regul. Toxicol. Pharm. 2014, 69:296-303. 10.1016/j.yrtph.2014.04.006.
6. Boxall A.B.A., Keller V.D.J., Straub J.O., Monteiro S.C., Fussell R., Williams R.J. Exploiting monitoring data in environmental exposure modeling and risk assessment of pharmaceuticals. Environ. Int. 2014, 73:176-185. 10.1016/j.envint.2014.07.018.
7. Brunton, L.L., Chabner, B.A., Knollmann, B.C., 2012. As Bases Farmacológicas da Terapêutica de Goodman e Gilman. 12. ed. AMGH, Porto Alegre. 2112 p. ISBN: 9788580551167.
8. Carlsson C., Johansson A.K., Alvan G., Bergman K., Kühler T. Are pharmaceuticals potent environmental pollutants? Part I: environmental risk assessments of selected active pharmaceutical ingredients. Sci. Total Environ. 2006, 364:67-87. 10.1016/j.scitotenv.2005.06.035.
9. Celiz M.D., Tso J., Aga D.S. Pharmaceutical metabolites in the environment: analytical challenges and ecological risks. Environ. Toxicol. Chem. 2009, 28:2473-2484. 10.1897/09-173.1.
10. Claessens M., Vanhaecke L., Wille K., Janssens C.R. Emerging contaminants in Belgian marine waters: Single toxicant and mixture risks of pharmaceuticals. Mar. Pollut. Bull. 2013, 71:41-50. 10.1016/j.marpolbul.2013.03.039.
11. Cleuvers M. Aquatic ecotoxicity of pharmaceuticals including the assessment of combination effects. Toxicol. Lett. 2003, 142:185-194. 10.1016/S0378-4274(03)00068-7.
12. Cleuvers M. Initial risk assessment for three β-blockers found in the aquatic environment. Chemosphere 2005, 59:199-205. 10.1016/j.chemosphere.2004.11.090.
13. Czech B., JośKo I., Oleszczuk P. Ecotoxicological evaluation of selected pharmaceuticals to Vibrio fischeri and Daphnia magna before and after photooxidation process. Ecotox. Environ. Safe. 2014, 104:247-253. 10.1016/j.ecoenv.2014.03.024.
14. Dietrich S., Ploessl F., Bracher F., Laforsch C. Single and combined toxicity of pharmaceuticals at environmentally relevant concentrations in Daphnia magna - a multigenerational study. Chemosphere 2010, 79:60-66. 10.1016/j.chemosphere.2009.12.069.
15. Escher B.I., Bramaz N., Richter M., Lienert J. Comparative ecotoxicological hazard assessment of beta-blockers and their human metabolites using a mode-of-action-based test battery and a QSAR approach. Environ. Sci. Technol. 2006, 40:7402-7408. 10.1021/es052572v.
16. European Commission, 2003. Technical Guidance Document on Risk Assessment in Support of Commission Directive 93/67/EEC on Risk Assessment For New Notified Substances, Commission Regulation (EC) No 1488/94 on Risk Assessment For Existing Substances, Directive 98/8/EC of the European Parliament And Of The Council Concerning The Placing Of Biocidal Products On The Market-Part II, 328 pp.
17. European Communities, 1967. Council Directive On The Approximation Of Laws, Regulations And Administrative Provisions Relating To The Classification, Packing and Labeling Of Dangerous Substances (67/548/EEC). Annex VI: General Classification And Labeling Requirements For Dangerous Substances And Preparations.
18. Fatta-Kassinos D., Vasquez M.I., Kümmerer K. Transformation products of pharmaceuticals in surface waters and wastewater formed during photolysis and advanced oxidation processes - degradation, elucidation of byproducts and assessment of their biological potency. Chemosphere 2011, 85:693-709. 10.1016/j.chemosphere.2011.06.082.
19. Feiner M., Laforsch C., Letzel T., Geist J. Sublethal effects of the beta-blocker sotalol at environmentally relevant concentrations on the New Zealand mudsnail Potamopyrgus antipodarum. Environ. Toxicol. Chem. 2014, 33:2510-2515. 10.1002/etc.2699.
20. Ferrari B., Mons R., Vollat B., Fraysse B., Paxéus N., Giudice R.L., Pollio A., Garric J. Environmental risk assessment of six human pharmaceuticals: are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment?. Environ. Toxicol. Chem. 2004, 23:1344-1354. 10.1897/03-246.
21. Fick, J., Lindberg, R.H., Kaj, L., Brorström-Lundén, E., 2011. Results From The Swedish National Screening Programme 2010-Subreport 3. Pharmaceuticals. Swedish Environmental Research Institute.
22. Franzellitti S., Buratti S., Valbonesi P., Capuzzo A., Fabbri E. The β-blocker propranolol affects cAMP dependent signaling and induces the stress response in Mediterranean mussels, Mytilus galloprovincialis. Aquat. Toxicol. 2011, 101:299-308. 10.1016/j.aquatox.2010.11.001.
23. Franzellitti S., Buratti S., Valbonesi P., Fabbri E. The mode of action (MoA) approach reveals interactive effects of environmental pharmaceuticals on Mytilus galloprovincialis. Aquat. Toxicol. 2013, 140-141:249-256. 10.1016/j.aquatox.2013.06.005.
24. Fraysse B., Garric J. Prediction and experimental validation of acute toxicity of β-blockers in Ceriodaphnia dubia. Environ. Toxicol. Chem. 2005, 24:2470-2476. 10.1897/04-541R.1.
25. Frias, M.C. 2013. Uso De Genéricos Contra Hipertensão Cresce 190%. (accessed 02.02.15). http://www1.folha.uol.com.br/colunas/mercadoaberto/2013/08/1323813-uso-de-genericos-contra-hipertensao-cresce-190.shtml.
26. Godoy A.A., Kummrow F., Pamplin P.A.Z. Ecotoxicological evaluation of propranolol hydrochloride and losartan potassium to Lemna minor L. (1753) individually and in binary mixtures. Ecotoxicology 2015, 10.1007/s10646-015-1455-3.
27. Grung M., Källqvist T., Sakshaug S., Skurtveit S., Thomas K.V. Environmental assessment of Norwegian priority pharmaceuticals based on the EMEA guideline. Ecotox. Environ. Safe. 2008, 71:328-340. 10.1016/j.ecoenv.2007.10.015.
28. Gu Q., Burt V.L., Dillon C.F., Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: The National Health And Nutrition Examination Survey, 2001 to 2010. Circulation 2012, 126:2105-2114. 10.1161/CIRCULATIONAHA.112.096156.
29. Gust M., Fortier M., Garric J., Fournier M., Gagné F. Effects of short-term exposure to environmentally relevant concentrations of different pharmaceutical mixtures on the immune response of the pond snail Lymnaea stagnalis. Sci. Total Environ. 2013, 445-446:210-218. 10.1016/j.scitotenv.2012.12.057.
30. Hernando M.D., Petrović M., Fernández-Alba A.R., Barceló D. Analysis by liquid chromatography-electrospray ionization tandem mass spectrometry and acute toxicity evaluation for β-blockers and lipid-regulating agents in wastewater samples. J. Chromatogr. A 2004, 1046:133-140. 10.1016/j.chroma.2004.06.102.
31. Huggett D.B., Brooks B.W., Peterson B., Foran C.M., Schlenk D. Toxicity of select beta adrenergic receptor-blocking pharmaceuticals (B-Blockers) on aquatic organisms. Arch. Environ. Contam. Toxicol. 2002, 43:229-235. 10.1007/s00244-002-1182-7.
32. Isidori M., Lavorgna M., Nardelli A., Pascarella L., Parrella A. Toxic and genotoxic evaluation of six antibiotics on non-target organisms. Sci. Total Environ. 2005, 346:87-98. 10.1016/j.scitotenv.2004.11.017.
33. Kasprzyk-Hordern B., Dinsdale R.M., Guwy A.J. The removal of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs during wastewater treatment and its impact on the quality of receiving waters. Wat. Res. 2009, 43:363-380. 10.1016/j.watres.2008.10.047.
34. Kim Y., Choi K., Jung J., Park S., Kim P.G., Park J. Aquatic toxicity of acetaminophen, carbamazepine, cimetidine, diltiazem and six major sulfonamides, and their potential ecological risks in Korea. Environ. Int. 2007, 33:370-375. 10.1016/j.envint.2006.11.017.
35. Kim J.W., Ishibashi H., Yamauchi R., Ichikawa N., Takao Y., Hirano M., Koga M., Arizono K. Acute toxicity of pharmaceutical and personal care products on freshwater crustacean (Thamnocephalus platyurus) and fish (Oryzias latipes). J. Toxicol. Sci. 2009, 34:227-232. 10.2131/jts.34.227.
36. Klosterhaus S.L., Grace R., Hamilton M.C., Yee D. Method validation and reconnaissance of pharmaceuticals, personal care products, and alkylphenols in surface waters, sediments, and mussels in an urban estuary. Environ. Int. 2013, 54:92-99. 10.1016/j.envint.2013.01.009.
37. Kostich M.S., Batt A.L., Lazorchak J.M. Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation. Environ. Pollut. 2014, 184:354-359. 10.1016/j.envpol.2013.09.013.
38. Küster A., Alder A.C., Escher B.I., Duis K., Fenner K., Garric J., Hutchinson T.H., Lapen D.R., Péry A., Römbke J., Snape J., Ternes T., Topp E., Wehrhan A., Knacker T. Environmental risk assessment of human pharmaceuticals in the European Union: a case study with the β-Blocker atenolol. Integr. Environ. Assess. Manag. 2010, 6:514-523. 10.1897/IEAM_2009-050.1.
39. Larsson D.G.K., de Pedro C., Paxeus N. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J. Hazard. Mater. 2007, 148:751-755. 10.1016/j.jhazmat.2007.07.008.
40. Le T.H., Lim E.S., Lee S.K., Park J.S., Kim Y.H., Min J. Toxicity evaluation of verapamil and tramadol based on toxicity assay and expression patterns of Dhb, Vtg, Arnt, CYP4 and CYP314 in Daphnia magna. Environ. Toxicol. 2011, 26:515-523. 10.1002/tox.20665.
41. Li Z.H., Li P., Randak T. Ecotoxicological effects of short-term exposure to a human pharmaceutical verapamil in juvenile rainbow trout (Oncorhynchus mykiss). Comp. Biochem. Phys. C 2010, 152:385-391. 10.1016/j.cbpc.2010.06.007.
42. López-Roldán R., de Alda M.L., Gros M., Petrovic M., Martín-Alonso J., Braceló D. Advanced monitoring of pharmaceuticals and estrogens in the Llobregat River basin (Spain) by liquid chromatography-triple quadrupole-tandem mass spectrometry in combination with ultra-performance liquid chromatography-time of flight-mass spectrometry. Chemosphere 2010, 80:1337-1344. 10.1016/j.chemosphere.2010.06.042.
43. López-Serna R., Pérez S., Ginebreda A., Petrović M., Barceló D. Fully automated determination of 74 pharmaceuticals in environmental and waste waters by online solid phase extraction-liquid chromatography-electrospray-tandem mass spectrometry. Talanta 2010, 83:410-424. 10.1016/j.talanta.2010.09.046.
44. López-Serna R., Petrović M., Barceló D. Development of a fast instrumental method for the analysis of pharmaceuticals in environmental and wastewaters based on ultra-high performance liquid chromatography (UHPLC)-tandem mass spectrometry (MS/MS). Chemosphere 2011, 85:1390-1399. 10.1016/j.chemosphere.2011.07.071.
45. López-Serna R., Jurado A., Vázquez-Suñé E., Carrera J., Petrović M., Barceló D. Occurrence of 95 pharmaceuticals and transformation products in urban groundwaters underlying the metropolis of Barcelona, Spain. Environ. Pollut. 2013, 174:305-315. 10.1016/j.envpol.2012.11.022.
46. Madureira T.V., Rocha M.J., Cruzeiro C., Rodrigues I., Monteiro R.A.F., Rocha E. The toxicity potential of pharmaceuticals found in the Douro River estuary (Portugal): evaluation of impacts on fish liver, by histopathology, stereology, vitellogenin and CYP1A immunohistochemistry, after sub-acute exposures of the zebrafish model. Environ. Toxicol. Phar. 2012, 34:34-45. 10.1016/j.etap.2012.02.007.
47. Margot J., Kienle C., Magnet A., Weil M., Rossi L., de Alencastro L.F., Abegglen C., Thonney D., Chèvre N., Schärer M., Barry D.A. Treatment of micropollutants in municipal wastewater: ozone or powdered activated carbon?. Sci. Total Environ. 2013, 461-462:480-498. 10.1016/j.scitotenv.2013.05.034.
48. Maszkowska J., Stolte S., Kumirska J., Lukaszewicz P., Mioduszewska K., Puckowski A., Caban M., Wagil M., Stepnowski P., Bialk-Bielińska A. Beta-blockers in the environment: Part I. Mobility and hydrolysis study. Sci. Total Environ. 2014, 493:1112-1121. 10.1016/j.scitotenv.2014.06.023.
49. Maszkowska J., Stolte S., Kumirska J., Lukaszewicz P., Mioduszewska K., Puckowski A., Caban M., Wagil M., Stepnowski P., Bialk-Bielińska A. Beta-blockers in the environment: Part II. Ecotoxicity study. Sci. Total. Environ. 2014, 493:1122-1126. 10.1016/j.scitotenv.2014.06.039.
50. Maurer M., Escher B.I., Richle P., Schaffner C., Alder A.C. Elimination of β-blockers in sewage treatment plants. Wat. Res. 2007, 41:1614-1622. 10.1016/j.watres.2007.01.004.
51. Minguez L., Pedelucq J., Farcy E., Ballandonne C., Budzinski H., Halm-Lemeille M.P. Toxicities of 48 pharmaceuticals and their freshwater and marine environmental assessment in northwestern France. Environ. Sci. Pollut. Res. Int. 2014, 10.1007/s11356-014-3662-5.
52. Nalecz-Jawecki G., Persoone G. Toxicity of selected pharmaceuticals to the anostracan crustacean Thamnocephalus platyurus - comparison of sublethal and lethal effect levels with the 1h Rapidtoxkit and the 24h Thamnotoxkit microbiotests. Environ. Sci. Pollut. R. 2006, 13:22-27. 10.1065/espr2006.01.005.
53. Nalecz-Jawecki G., Sawicki J. Influence of water hardness on the toxicity of selected pharmaceuticals and metals to the protozoa Spirostomum ambiguum and Tetrahymena termophila. Fresen. Environ. Bull. 2005, 14:873-877.
54. Nödler K., Hillebrand O., Idzik K., Strathmann M., Schiperski F., Zirlewagen J., Licha T. Occurrence and fate of the angiotensin II receptor antagonist transformation product valsartan acid in the water cycle - a comparative study with selected b-blockers and the persistent anthropogenic wastewater indicators carbamazepine and acesulfame. Wat. Res. 2013, 47:6650-6659. 10.1016/j.watres.2013.08.034.
55. Nödler K., Voutsa D., Licha T. Polar organic micropollutants in the coastal environment of different marine systems. Mar. Pollut. Bull. 2014, 85:50-59. 10.1016/j.marpolbul.2014.06.024.
56. Petersen K., Heiaas H.H., Tollefsen K.E. Combined effects of pharmaceuticals, personal care products, biocides and organic contaminants on the growth of Skeletonema pseudocostatum. Aquat. Toxicol. 2014, 150:45-54. 10.1016/j.aquatox.2014.02.013.
57. Piram A., Salvador A., Verne C., Herbreteau B., Faure R. Photolysis of β-blockers in environmental waters. Chemosphere 2008, 73:1265-1271. 10.1016/j.chemosphere.2008.07.018.
58. Pomati F., Cotsapas C.J., Castiglioni S., Zuccato E., Calamari D. Gene expression profiles in zebrafish (Danio rerio) liver cells exposed to a mixture of pharmaceuticals at environmentally relevant concentrations. Chemosphere 2007, 70:65-73. 10.1016/j.chemosphere.2007.07.048.
59. PróGenéricos - Associação Brasileira Das Indústrias De Medicamentos Genéricos, 2013. Saiba Quais São Os Genéricos Mais Vendidos No País. (accessed 02.02.15). http://www.progenericos.org.br/index.php/noticias/325-saiba-quais-sao-os-genericos-mais-vendidos-no-pais.
60. Radjenovic J., Petrovic M., Barceló D. Analysis of pharmaceuticals in wastewater and removal using a membrane bioreactor. Anal. Bioanal. Chem. 2007, 387:1365-1377. 10.1007/s00216-006-0883-6.
61. Rhee J.S., Jeong C.B., Kim B.M., Lee J.S. P-glycoprotein (P-gp) in the monogonont rotifer, Brachionus koreanus: molecular characterization and expression in response to pharmaceuticals. Aquat. Toxicol. 2012, 114-115:104-118. 10.1016/j.aquatox.2012.02.009.
62. Roberts P.H., Thomas K.V. The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. Sci. Total Environ. 2006, 356:143-153. 10.1016/j.scitotenv.2005.04.031.
63. Romero V., De la Cruz N., Dantas R.F., Marco P., Giménez J., Esplugas S. Photocatalytic treatment of metoprolol and propranolol. Catal. Today 2011, 161:115-120. 10.1016/j.cattod.2010.09.026.
64. 2. Appl. Catal. B-Environ. 2013, 129:13-29. 10.1016/j.apcatb.2012.09.023.
65. Santos L.H.M.L.M., Araújo A.N., Fachini A., Pena A., Delerue-Matos C., Montenegro M.C.B.S.M. Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. J. Hazard. Mater. 2010, 175:45-95. 10.1016/j.jhazmat.2009.10.100.
66. Santos L.H.M.L.M., Gros M., Rodriguez-Mozaz S., Delerue-Matos C., Pena A., Barceló D., Montenegro M.C.B.S.M. Contribution of hospital effluents to the load of pharmaceuticals in urban wastewaters: identification of ecologically relevant pharmaceuticals. Sci. Total Environ. 2013, 461-462:302-316. 10.1016/j.scitotenv.2013.04.077.
67. Sauvé S., Desroirers M. A review of what is an emerging contaminant. Chem. Cent. J. 2014, 8:15. 10.1186/1752-153X-8-15.
68. Steibach C., Burkina V., Fedorova G., Grabicova K., Stara A., Velisek J., Zlabek V., Schmidt-Posthaus H., Grabic R., Kroupova H.K. The sub-lethal effects and tissue concentration of the human pharmaceutical atenolol in rainbow trout (Oncorhynchus mykiss). Sci. Total Environ. 2014, 497-498:209-218. 10.1016/j.scitotenv.2014.07.111.
69. Steinbach C., Fedorova G., Prokes M., Grabicova K., Machova J., Grabic R., Valentova O., Kroupova H.K. Toxic effects, bioconcentration and depuration of verapamil in the early life stages of common carp (Cyprinus carpio L.). Sci. Total Environ. 2013, 461-462:198-206. 10.1016/j.scitotenv.2013.05.002.
70. Sun L., Xin L., Peng Z., Jin R., Jin Y., Qian H., Fu Z. Toxicity and enantiospecific differences of two β-blockers, propranolol and metoprolol, in the embryos and larvae of zebrafish (Danio rerio). Environ. Toxicol. 2014, 29:1367-1378. 10.1002/tox.21867.
71. Taylor D., Senac T. Human pharmaceutical products in the environment-the "problem" in perspective. Chemosphere 2014, 115:95-99. 10.1016/j.chemosphere.2014.01.011.
72. Ternes T.A. Occurrence of drugs in German sewage treatment plants and rivers. Wat. Res. 1998, 32:3245-3260. 10.1016/S0043-1354(98)00099-2.
73. van den Brandhof E.J., Montforts M. Fish embryo toxicity of carbamazepine, diclofenac and metoprolol. Ecotox. Environ. Safe. 2010, 73:1862-1866. 10.1016/j.ecoenv.2010.08.031.
74. Vannini C., Domingo G., Marsoni M., De Mattia F., Labra M., Castiglioni S., Bracale M. Effects of a complex mixture of therapeutic drugs on unicellular algae Pseudokirchneriella subcapitata. Aquat. Toxicol. 2011, 101:459-465. 10.1016/j.aquatox.2010.10.011.
75. Vasquez M.I., Lambrianides A., Schneider M., Kümmerer K., Fatta-Kassinos D. Environmental side effects of pharmaceutical cocktails: what we know and what we should know. J. Hazard. Mater. 2014, 279:169-189. 10.1016/j.jhazmat.2014.06.069.
76. Verlicchi P., Aukidy M.A., Galletti A., Petrovic M., Barceló D. Hospital effluent: investigation of the concentrations and distribution of pharmaceuticals and environmental risk assessment. Sci. Total Environ. 2012, 430:109-118. 10.1016/j.scitotenv.2012.04.055.
77. Walker S., McEldowney S. Molecular docking: a potential tool to aid ecotoxicity testing in environmental risk assessment of pharmaceuticals. Chemosphere 2013, 93:2568-2577. 10.1016/j.chemosphere.2013.09.074.
78. Wilde M.L., Kümmerer K., Martins A.F. Multivariate optimization of analytical methodology and a first attempt to an environmental risk assessment of β-blockers in hospital wastewater. J. Braz. Chem. Soc. 2012, 23:1732-1740. 10.1590/S0103-50532012005000035.
79. Wille K., Noppe H., Verheyden K., Bussche J.V., de Wulf E., van Caeter P., Janssen C.R., de Brabander H.F., Vanhaecke L. Validation and application of an LC-MS/MS method for the simultaneous quantification of 13 pharmaceuticals in seawater. Anal. Bioanal. Chem. 2010, 397:1797-1808. 10.1007/s00216-010-3702-z.
80. Xiao J., Xie Y., Cao H. Organic pollutants removal in wastewater by heterogeneous photocatalytic ozonation. Chemosphere 2015, 121:1-17. 10.1016/j.chemosphere.2014.10.072.
81. Yamamoto N.S., Pereira C.D.S., Cortez F.S., Pusceddu F.H., Santos A.R., Toma W., Guimarães L.L. Avaliação dos efeitos biológicos adversos dos fármacos anti-hipertensivos Losartan e Valsartan em ouriço-do-mar Lytechinus variegatus (ECHINODERMATA, ECHINOIDEA). UNISANTA BioScience 2014, 3:27-32.